Can enteral nutrition therapy help Crohn's Disease patients achieve remission?
Enteral nutrition (EN) therapy involves using liquid formula diets, either exclusively (EEN) or partially (PEN), to provide nutrition while reducing inflammation. For Crohn's disease (CD), EN is a well-established treatment, particularly in children, and research shows it can induce clinical remission and even promote mucosal healing. The evidence is strongest for EEN in pediatric CD, but newer studies also support PEN combined with a Crohn's disease exclusion diet (CDED) in adults. This approach may be an alternative or complement to medications, especially for patients who prefer non-drug options or need to avoid corticosteroids.
What the research says
A 2024 network meta-analysis of 20 studies (7 randomized trials) in pediatric CD found that exclusive enteral nutrition (EEN) was significantly better than corticosteroids for inducing clinical remission (odds ratio 1.72) and far superior for mucosal healing (odds ratio 7.55) 7. This confirms EEN as a first-line therapy for children with mild to moderate CD.
In adults, a 2019 randomized trial compared a Crohn's disease exclusion diet (CDED) plus partial enteral nutrition (PEN) to standard EEN. Both groups achieved high remission rates at week 6 (75% for CDED+PEN vs. 59% for EEN), and CDED+PEN was better tolerated and maintained remission better at week 12 9. A 2023 review notes that PEN and CDED may be appropriate for inducing remission in some adult patients, though trials are ongoing 11.
A retrospective study of 750 Chinese IBD patients (400 with CD) reported that enteral nutrition therapy was associated with clinical remission in 60% of patients over 6 weeks, with improvements in nutritional markers and quality of life 5. The study used elemental and semi-elemental formulas more often in CD patients 5.
Overall, the evidence supports EN as an effective remission induction strategy, especially EEN in children and CDED+PEN in adults. However, EN is not a cure and is often used alongside other treatments. For patients who cannot tolerate or do not respond to EN, biologic therapies like adalimumab or ustekinumab are FDA-approved for moderate to severe CD 18.
What to ask your doctor
- Would exclusive enteral nutrition or a Crohn's disease exclusion diet with partial enteral nutrition be appropriate for my disease severity and location?
- How long would I need to follow the enteral nutrition therapy to see if it induces remission?
- What are the potential side effects or challenges of enteral nutrition, and how can I manage them?
- Can enteral nutrition be used together with my current medications, or is it a replacement?
- Are there specific formula types (elemental, semi-elemental, or polymeric) that are recommended for my case?
This question is drawn from common patient questions about Gastroenterology and answered using cited medical research. We do not provide individualized advice.